Search Free Newsletters

Pharma

Transforming health through business and innovation.

Novo Nordisk's latest weight loss drug deal is with an AI-powered research firm

ByShannon Carroll

Dozens of states want to block 23andMe from selling DNA info

Pfizer and other drug companies make 'no commitments' to the White House on lower drug prices

ByMichael Barclay

Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be next

ByShannon Carroll

Noom wants to be 'the Duolingo of health'

ByShannon Carroll

CVS and Express Scripts sued to block a new law restricting drug middlemen

How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

New U.S. drug prices doubled amid a shift toward treating rare diseases

ByKevin Williams

Cigna is putting a cap on weight loss drug costs

ByKevin Williams

Noom is offering smaller doses of compounded Wegovy for weight loss

ByShannon Carroll

23andMe just got bought out of bankruptcy

ByMichael Barclay

Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year

ByCatherine Baab

Trump's push for lower drug prices is just asking Big Pharma to make less money

Eli Lilly stock sinks as pharma misses out on the market rally

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

6 fast food chains rolling out frozen drinks for summer

ByKevin Williams

Weight Watchers goes bankrupt even as it tries to ride the Ozempic boom

Trump says pharmaceutical tariffs are coming. Here's what to expect

ByShannon Carroll

Weight loss drugs can help employers cut health care costs, study says

ByCatherine Arnst

Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%